IRCT20141224020427N4
Recruiting
Phase 2
Safety of allogenic mesenchymal stem cells derived exosome on disability of patients with acute ischaemic stroke: a randomised, open labled, placebo-controlled, phase 1 trial
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 5
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male acute ischemic patients aged 40\-80 years with symptoms of acute cerebral infarction of less than 24h from stroke onset.
- •Patients with a measurable focal neurological that must persist to the time of treatment without clinically meaningful improvement
- •Patients must have computerized tomography (CT) and / or magnetic resonance imaging (MRI) compatible with the clinical diagnosis of acute ischemic stroke in the territory of the middle cerebral artery before being included in the study.
- •Patients must have a score on the NIH Stroke Scale 8\-24,
- •Obtaining informed consent signed
Exclusion Criteria
- •Comatose patients.
- •brain tumour, cerebral oedema with compression of ventricles, cerebellar infarction or brainstem, or intraventricular, intracerebral or subarachnoid haemorrhage.
- •alcohol use Active infectious disease, including HIV, hepatitis B, Hepatitis
- •patients with dementia
- •Specify clinical conditions
- •Patients who are participating in another clinical trial.
- •Inability or unwillingness of individual for giving written informed consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal FracturesTibial Closed Diaphyseal Fractures.Fracture of shaft of tibiaIRCT201508061031N11Royan Institute40
Not yet recruiting
Not Applicable
The mesenchymal stem cell therapy for Hutchinson-Gilford Progeria syndromeEndocrine, nutritional and metabolic diseasesKCT0008336Inha University Hospital1
Completed
Not Applicable
Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipientsfibrosisrejection10038430NL-OMON40295eids Universitair Medisch Centrum12
Completed
Phase 1
Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus ErythematosusSystem; Lupus ErythematosusNCT03171194Medical University of South Carolina6
Not yet recruiting
Phase 1
Transplantation of stem cells for the treatment of type 1 diabetes.Type 1 diabetes mellitus (T1DM).Type 1 diabetes mellitusIRCT20210925052566N1Endocrinology and Metabolism Research Institute30